FUTURE OF HEALTHCARE

Medicago Announces Publication of Phase 3 COVID-19 Vaccine Study Results in New England Journal of Medicine

Medicago | May 06, 2022

Medicago Announces

Medicago announced the publication of the results from the Phase 3 study of COVIFENZ®, COVID-19 vaccine recombinant, adjuvanted, in the New England Journal of Medicine. The Phase 3 trial studied the two-dose regimen of COVIFENZ® given 21 days apart versus placebo in over 24,000 subjects aged 18 and above. Common side effects in the vaccine group included injection site pain, headache, fatigue, fever, muscle aches, and chills.

COVIFENZ® is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2  in individuals 18 to 64 years of age. The safety and efficacy of COVIFENZ® in individuals younger than 18 years of age or 65 years and older have not been established. COVIFENZ® has not yet received approval in other jurisdictions.

We are proud to have our Phase 3 clinical trial published in the esteemed New England Journal of Medicine to be shared with the larger scientific community. Medicago’s scientific team has dedicated decades to the development of our proprietary plant-based vaccine manufacturing platform, and we are thrilled to see our results disseminated in this way. We hope that this exchange of research and knowledge will encourage and inspire future innovation in biomedical science and clinical practice.”

Marc-André D’Aoust, Executive Vice President, Innovation, Development and Medical Affairs at Medicago

COVIFENZ® was authorized for use by Health Canada on February 24, 2022. This is the first authorized COVID-19 vaccine developed by a Canadian-headquartered company, and the first that uses a plant-based protein technology.

“The world needs a diverse range of vaccine options to continue to fight COVID-19, and we are proud to be able to contribute,” said Toshifumi Tada, CEO and President at Medicago.

About Medicago

Medicago is on a mission to help improve global public health using the power of plants. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare, Medicago is a pioneer in plant-based therapeutics. We are proudly rooted in Quebec, with manufacturing capacity in both Canada and the US. Our passionate and curious team of over 500 scientific experts and employees are dedicated to using our technology to provide rapid responses to emerging global health challenges, and to advancing therapeutics against life-threatening diseases worldwide. Medicago is an affiliated company of Mitsubishi Tanabe Pharma Corporation. 

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation, the majority parent company of Medicago, is one of the large Japanese pharmaceutical companies, with its headquarters in Osaka, Japan. It positions vaccines as one of its key R&D areas and is also working to develop new modalities of vaccines. MTPC will further contribute to the prevention of infectious diseases which is one of the world’s important social issues, by delivering a new option of plant-based VLP vaccine as a new type of vaccine. MTPC is a member of Mitsubishi Chemical Holdings Group. 

Spotlight

The Lenox Hill Hospital Health Sciences Library is open to all library users Monday through Friday from 9:00 AM to 5:00 PM. The library is accessible for physicians afterhours until 11:00 PM Monday through Friday and from 9:00 AM to 11:00 PM Saturday and Sunday by using the card swipe readers located at both entrances to the library.

Spotlight

The Lenox Hill Hospital Health Sciences Library is open to all library users Monday through Friday from 9:00 AM to 5:00 PM. The library is accessible for physicians afterhours until 11:00 PM Monday through Friday and from 9:00 AM to 11:00 PM Saturday and Sunday by using the card swipe readers located at both entrances to the library.

Related News

HEALTHTECH SECURITY

BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project

BeeKeeperAI and Novartis Biome | October 20, 2022

BeeKeeperAI, the pioneer in sightless computing on protected data, announced that it worked with scientists from Novartis Biome’s Evidence Lab and the University of California, San Francisco to train and validate an algorithm to predict instances of a rare childhood condition using real patient data from health records. This project marks the first time that confidential computing technology has been leveraged to support sightless computation by an algorithm against protected health information. “This project is an important milestone in the development of the rare disease solution by the Evidence Lab,” said Robin Roberts, Co-founder and Chief Operating Officer at Novartis Biome. “Rare diseases are often challenging to diagnose and if left untreated, they can significantly diminish a patient’s quality of life. With BeeKeeperAI, our scientists were able to securely access a large gold standard dataset that enabled us to improve the predictive capabilities of our algorithm, bringing us much closer to identifying patients early in the disease course and to improving their outcomes.” The Novartis Biome Evidence Lab was developed in collaboration with health systems and data providers as a space for health tech companies to test their digital solutions and identify ways to optimize and scale their offerings. BeeKeeperAI’s zero trust architecture supports sightless computing of algorithms against protected information. It uses advanced encryption within secure computing enclaves to enable data stewards and algorithm developers to collaborate without exposing the data or revealing important IP. The platform eliminates reliance on data deidentification or difficult to enforce contractual agreements that typically govern access to protected health information. “The traditional mechanisms for securing permission to use confidential patient information to develop healthcare AI are time-consuming and costly and that has slowed the pace of innovation in the field. We developed our platform with an eye towards addressing the constraints of existing approaches for accessing protected information and helping algorithm developers and data stewards collaborate far more effectively,” Michael Blum, MD, Co-founder and Chief Executive Officer at BeeKeeperAI The Novartis project leveraged Microsoft Azure’s confidential computing environment utilizing an Intel SGX secure enclave. Prior to moving the data into the secure enclave at UCSF, BeeKeeperAI worked with clinical and data science experts at UCSF to curate, harmonize, and encrypt data that included 28 pediatric patients diagnosed with the pediatric rare disease in question and an additional 2,000 matched controls. Simultaneously, BeeKeeperAI enabled the Novartis scientists to prepare the algorithm for the secure environment, including encrypting and uploading it to the BeeKeeperAI cloud platform. Encrypting both the data and the algorithm ensured that they remain protected throughout the computing process. Once the encrypted algorithm and data were in the secure enclave, they were decrypted, and the algorithm was allowed to compute against the identifiable data. The process was fully automated and sightless. The output of the computation was a report that provided performance metrics. Novartis scientists used the feedback from the BeeKeeperAI platform to fine-tune the algorithm and rerun it against the data. Through this iterative loop, they significantly improved the predictive capabilities of their solution to detect patients with the rare condition. The solution is now ready for further validation at additional academic medical centers known for treating this rare condition. BeeKeeperAI will be participating in the Novartis Biome's "Closing the Digital Divide: Validation through Partnership" event on Wednesday, October 19, where they will share more details of the healthcare AI project with Novartis Biome and UCSF. About Novartis Biome Novartis Biome is a bridge to help partners become an extension of Novartis own teams, working with them as easily and productively as possible to jointly innovate and co-develop digital solutions at scale. The Biome is committed to partnering with the best in the ecosystem to combine deep scientific experience with the expertise of the tech world to develop – and crucially – scale digital solutions that improve and extend patients’ lives. About BeeKeeperAI BeeKeeperAI is the pioneer in confidential, sightless computing within a zero-trust architecture for the development and deployment of AI in healthcare and other privacy protected data. BeeKeeperAI is accelerating the broader availability of AI-powered solutions that will help to redefine the future of healthcare and commerce.

Read More

HEALTH TECHNOLOGY

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

IQVIA | September 29, 2022

IQVIA a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc’s third-party validation demonstrates that IQVIA’s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. “At IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “IQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.” TRUSTArc maps it’s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it’s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development. “Achieving a GDPR validation demonstrates IQVIA’s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves. Organizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.” Chris Babel, CEO, TRUSTArc About IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.

Read More

FUTURE OF HEALTHCARE

DispatchHealth Raises More Than $330 Million to Expand Its Technology-Enabled Ecosystem of High Acuity Care in the Home

DispatchHealth | November 24, 2022

DispatchHealth, the nation's first comprehensive in-home, high acuity medical care provider announced it has raised more than $330 million in combined equity and debt financing. The equity round of $259 million was led by Optum Ventures, with participation from new investors Adams Street Partners, Blue Shield of California, among others, and continued support from existing investors Humana, Echo Health Ventures, Questa Capital and Oak HC/FT. K2 HealthVentures, Silicon Valley Bank and SVB Capital provided debt financing of $75 million, with up to an additional $75 million available for growth initiatives, bringing the total raised to more than $400 million. In the United States, $4 trillion is spent on healthcare annually and it is projected to exceed $6 trillion by 2028. With more than a third of this spend on care delivered in traditional brick-and-mortar facilities, the healthcare industry has reached a watershed moment. DispatchHealth's in-home, high acuity care model aligns health plans, health systems, at-risk provider groups and patients with complex care needs by delivering a value-based alternative to high-cost settings such as the emergency room, hospital ward or skilled nursing facility, reducing medical costs while improving clinical outcomes and patient and provider satisfaction. "For the past seven years, we have been building a comprehensive ecosystem of high acuity care in the home. Our proven approach to delivering healthcare to complex patients in their homes will continue to transform healthcare. This round of funding is a testament to what we and our passionate team members have created at DispatchHealth and the belief our partners have in our leading-edge care model." Dr. Mark Prather, Co-Founder and CEO of DispatchHealth Today, DispatchHealth provides high acuity care to complex patients across 34 states and has developed innovative relationships with health plans, provider groups, health systems, employers, senior living facilities, and home health organizations to deliver a better, more coordinated healthcare experience. DispatchHealth is also one of the largest and most experienced providers of Advanced Care, a hospital alternative, and Extended Care, a skilled nursing facility alternative. To coordinate the complex ecosystem of in-home care, DispatchHealth has created an operating system for high acuity care in the home. The proprietary technology platform uses real-time data insights to manage all aspects of the in-home care experience, including logistics, onboarding, risk stratification, care coordination and analytics that elevate the clinical practice and drive improved outcomes. DispatchHealth will use the financing to Expand its proven in-home high acuity care ecosystem in existing markets and key expansion markets; Accelerate its technology platform development to deliver consistent and scalable patient-centric care; and, Strategically grow its portfolio of in-home system of care and last mile care capabilities. "DispatchHealth is transforming the healthcare industry by improving access to outcomes-driven, high-quality, in-home care and delivering on the enhanced experience patients deserve. Optum Ventures is honored to deepen our relationship with DispatchHealth and its experienced leadership team as they continue to expand their reach of high acuity, in-home care to serve patients with complex care needs across the nation," said Laura Veroneau, Managing Partner at Optum Ventures. "DispatchHealth's comprehensive and unique ecosystem of in-home care is compelling. Adams Street is thrilled to support DispatchHealth as they expand their system of care, particularly their high acuity hospitalization substitution model. We believe DispatchHealth is positioned to catalyze important and necessary advances in the healthcare industry," said Tom Bremner, a Partner at Adams Street Partners. About DispatchHealth  DispatchHealth brings the power of the hospital to the comfort of the home. DispatchHealth is building the leading in-home system of care and offers on-demand acute care and an advanced level of medical care for people of all ages in the comfort of their own homes. DispatchHealth's emergency medicine and internal medicine trained medical teams are equipped with all the tools necessary to treat common to complex injuries and illnesses. DispatchHealth works closely with payers, providers, health systems, EMS, employer groups and others to deliver care in the home to reduce unnecessary emergency room visits, hospital stays and readmissions. Acute Care medical teams are available seven days a week, evenings and holidays and can be requested online or via a quick phone call. DispatchHealth is partnered with most major insurance companies. About Optum Ventures Optum Ventures is the independent venture fund of UnitedHealth Group. Optum Ventures invests in digital health companies that use data and insights to help improve consumers' access to healthcare services and how care is delivered and paid for, and that make the health care system more reliable and easier to navigate. About Adams Street Partners Adams Street Partners is a global private markets investment manager with investments in more than thirty countries across five continents. The firm is 100% employee-owned and has $50 billion in assets under management. Adams Street strives to generate actionable investment insights across market cycles by drawing on 50 years of private markets experience, proprietary intelligence, and trusted relationships. Adams Street has offices in Austin, Beijing, Boston, Chicago, London, Menlo Park, Munich, New York, Seoul, Singapore, and Tokyo.

Read More